IB-T101 injection for advanced clear cell kidney cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This open-label, single-center, dose escalation and extension study evaluates the safety, efficacy, and pharmacokinetics of IB-T101 in adult patients with advanced clear renal cell carcinoma. Participants will receive the IB-T101 injection, and the study aims to determine the appropriate dosing and monitor patient responses. The trial is designed for patients who meet specific eligibility criteria, including performance status and expected survival time.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Voluntarily join the study, signed informed consent form， willing and able to comply with the study protocol;
2. Age ≥18 years old;
3. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;
4. Expected survival time of ≥ 3 months;

Exclusion Criteria:

1. CNS dysfunction with clinical significance. For example, seizures, cerebral ischemia/hemorrhage, dementia, cerebellar diseases, cerebral edema, reversible posterior encephalopathy syndrome, or any autoimmune disease involving the CNS.
2. Any form of primary and acquired immunodeficiency (such as severe combined immunodeficiency). Known human immunodeficiency virus (HIV) positive subjects
3. Have experienced myocardial infarction or unstable angina within the 6 months prior to screening
4. Pleural effusion requiring drainage for symptom management within 28 days prior to screening

Where it's running

• Tongji hospital, Huazhong University of Science and Technology
  Wuhan, Hubei, China Recruiting

Study contacts

• Study coordinator: Bo Liu
• Email: liubo0124@163.com
• Phone: 15927168582

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• GT801 injection for moderate-to-severe refractory autoimmune disease

  This trial will test whether GT801 injections are safe and help adults with moderate-to-severe autoimmune disease that has not responded to standard treatments.

  Recruiting Early Phase 1 Grit Biotechnology · Shanghai, Shanghai Municipality · NCT07333118

• GT729 universal cell injection for refractory or relapsed chronic graft-versus-host disease

  This trial will try GT729 universal cell injections in adults whose chronic graft-versus-host disease has not responded to at least two prior systemic treatments after an allogeneic stem cell transplant.

  Recruiting Early Phase 1 Grit Biotechnology · Tianjin, Tianjin Municipality · NCT07253259

• GT801 injection for adults with relapsed/refractory CD19-positive B-cell cancers and autoimmune hemolytic anemia

  This trial will test whether GT801 injections help adults with CD19-positive B-cell cancers (B-ALL, CLL, B-NHL) or autoimmune hemolytic anemia that have returned or not responded to prior treatments.

  Recruiting Early Phase 1 Grit Biotechnology · Zhengzhou, Henan and 1 other locations · NCT07205315

• GT719 injection for people with moderate to severe refractory autoimmune disease.

  This trial will test whether GT719 injections are safe and can help adults aged 18-65 whose moderate to severe autoimmune disease has not responded to other treatments.

  Recruiting Early Phase 1 Grit Biotechnology · Nantong, Jiangsu · NCT07132112

• GT719 universal cell injection for adults with relapsed or refractory CD19-positive B-cell cancers

  This trial will test whether GT719, a universal CD19-targeting cell injection, is safe and can induce remissions in adults with relapsed or refractory CD19-positive B-cell lymphoma or B-cell acute lymphoblastic leukemia.

  Recruiting Early Phase 1 Grit Biotechnology · Ganzhou, Jiangxi · NCT07131254

• GT719 injection for adults with moderate to severe refractory autoimmune diseases

  This trial will try giving GT719 injections to 10 adults with moderate to severe autoimmune diseases that haven't responded to standard treatments to see if the treatment is safe and helps control their disease.

  Recruiting Early Phase 1 Grit Biotechnology · Shanghai · NCT07122076

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.